



Antibody Research in the COVID-19 Pandemic

Guest Editor:

Dr. Surender Khurana

Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD 20993, USA

Deadline for manuscript submissions:

closed (31 January 2024)

Message from the Guest Editor

Dear Colleagues,

The COVID-19 pandemic shook the world globally with dreadful implications, but also demonstrated an unprecedented collective response to the SARS-CoV-2 infection. To address global public health, this Special Issue will discuss the methods and approaches to illustrate and profile the immune response following infection and vaccination.

We would like to invite you to share your work on vaccines and/or infection (both COVID-19 and other diseases), with an emphasis on immune response studies.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- The antibody response following vaccination.
- Immune response following infection.
- Role of number and dosage of vaccination in immune response.
- The safety of vaccines.
- Impact of monovalent vs bivalent vaccines.
- Circulating and emerging SARS-CoV-2 variants.

We look forward to receiving your contributions.

Dr. Surender Khurana
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)